TY - JOUR
T1 - Erythropoietin-dependent suppression of the expression of the β subunits of the interleukin-3 receptor during erythroid differentiation
AU - Carta, Claudio
AU - Campisi, Silvana
AU - Migliaccio, Giovanni
AU - Migliaccio, Anna Rita
N1 - Funding Information:
The authors are grateful to Drs. Atsushi Miyajima (University of Tokyo, Tokyo, Japan) and Clive Wood (Genetic Institute, Cambridge, MA) for helpful discussions and Margaret Oppenheimer for editorial assistance. This study was supported by a Johnson and Johnson Focus Giving Grant and institutional funds of the Istituto Superiore di Sanita, Rome, Italy.
PY - 2000/10
Y1 - 2000/10
N2 - To clarify how erythroid cells lose their response to interleukin-3 (IL-3), we analyzed the expression of the α (αIL-3) and β (βIL-3/βcom) subunits of its receptor in a panel of murine cell lines immortalized at different stages of hemopoietic differentiation. The panel was composed by the mast cell line 32D and by its granulo-monocytic (32D GM), granulocytic (32D G), and erythroid (32D Epo1.1 and Epo) subclones. The 32D Epo cells grow only in erythropoietin (EPO) while the Epo1.1 subclone grows in either EPO or IL-3. The phenotype of these cells is that of early (expression of globins and erythroid-specific carbonic anhydrase II) and late (also expression of the erythroid-specific band 4.1 mRNA) erythroblasts when they grow in IL-3 or EPO, respectively. All the cell lines expressed comparable levels of αIL-3. In contrast, the expression of βIL-3gbcom was restricted to cells growing in IL-3 and was barely detectable in 32D Epo and 32D Epo1.1 cells growing in EPO. When switched from EPO to IL-3, 32D Epo1.1 cells expressed 10 times more βIL-3/βcom by rapidly activating (within 1 h) their transcription rate. When reexposed to EPO, 32D Epo1.1 cells first expressed (1-6 h) more βIL-3/βcom >(2 times) but suppressed such an expression at later time points (by 48 h). The βIL-3/βcom mRNA half-life was also different when 32D Epo1.1 cells grew in EPO or IL-3 (2-3 h vs >5 h, respectively). These results indicate that EPO specifically induces transcriptional and posttranscriptional downmodulation of βIL-3/βcom expression in late erythroid cells.
AB - To clarify how erythroid cells lose their response to interleukin-3 (IL-3), we analyzed the expression of the α (αIL-3) and β (βIL-3/βcom) subunits of its receptor in a panel of murine cell lines immortalized at different stages of hemopoietic differentiation. The panel was composed by the mast cell line 32D and by its granulo-monocytic (32D GM), granulocytic (32D G), and erythroid (32D Epo1.1 and Epo) subclones. The 32D Epo cells grow only in erythropoietin (EPO) while the Epo1.1 subclone grows in either EPO or IL-3. The phenotype of these cells is that of early (expression of globins and erythroid-specific carbonic anhydrase II) and late (also expression of the erythroid-specific band 4.1 mRNA) erythroblasts when they grow in IL-3 or EPO, respectively. All the cell lines expressed comparable levels of αIL-3. In contrast, the expression of βIL-3gbcom was restricted to cells growing in IL-3 and was barely detectable in 32D Epo and 32D Epo1.1 cells growing in EPO. When switched from EPO to IL-3, 32D Epo1.1 cells expressed 10 times more βIL-3/βcom by rapidly activating (within 1 h) their transcription rate. When reexposed to EPO, 32D Epo1.1 cells first expressed (1-6 h) more βIL-3/βcom >(2 times) but suppressed such an expression at later time points (by 48 h). The βIL-3/βcom mRNA half-life was also different when 32D Epo1.1 cells grew in EPO or IL-3 (2-3 h vs >5 h, respectively). These results indicate that EPO specifically induces transcriptional and posttranscriptional downmodulation of βIL-3/βcom expression in late erythroid cells.
KW - 32D subclones
KW - Erythroid differentiation
KW - Erythropoietin
KW - IL-3 receptor
KW - Reception interactions
UR - https://www.scopus.com/pages/publications/0034523224
U2 - 10.1006/bcmd.2000.0327
DO - 10.1006/bcmd.2000.0327
M3 - Article
C2 - 11112384
AN - SCOPUS:0034523224
SN - 1079-9796
VL - 26
SP - 467
EP - 478
JO - Blood Cells, Molecules, and Diseases
JF - Blood Cells, Molecules, and Diseases
IS - 5
ER -